OXB has reported record new client additions and reiterated Revenue guidance of up to £200m for 2026, as it lays out an ambition to reach around £500m of revenue by the end of the decade.
Oxford Biomedica (LSE:OXB), which trades as OXB, has kept investors focused on its growth trajectory following interim results published on 22 September. The FTSE 250 cell and gene therapy Manufacturing specialist reported rising revenue, a record number of new clients and a substantial contracted order book, while confirming targets that point to rapid expansion next year. Directors have also been active in the market, with several dealing notifications filed in late September and on 6 October.
Revenue growth and client momentum
Revenue for the six months to 30 June rose 9% to £79.8m, or 10% on a constant currency basis, with manufacturing services revenue up around 20%. The company remains loss-making at the operating level as it scales its global footprint. The operating EBITDA loss narrowed slightly to £7.8m, while on an adjusted basis excluding one-off items and currency effects it improved to a loss of £2.5m. The operating loss widened to £29.1m, including a £7.6m Impairment relating to its French assets.
The commercial picture was more striking. OXB signed 17 new clients in the half and a further four after the period end, taking its total to 50 clients and 59 client programmes. The non-risk-adjusted pipeline grew about 30% to roughly $713m. Chief executive Frank Mathias described the first half as commercially solid, with record new client wins, and highlighted that the group's site in Durham, North Carolina, is now operational and serving clients.
Guidance and medium-term targets
OXB reiterated its guidance for 2026 revenue of £180m to £200m at constant currency, with an EBITDA Margin in the mid-single digits excluding one-off costs. Visibility is relatively high, with about £168m of forecast 2026 revenue already covered by contracted orders and a total revenue Backlog of around £193m at the end of June.
Looking further ahead, the company is targeting revenue growth of 25% to 30% in 2027, alongside at least double-digit EBITDA margins. Its longer-term ambition is to reach about £500m of revenue by 2030, with EBITDA margins eventually approaching 30%. Those targets imply a significant step-up in scale and profitability from current levels.
Cash position under scrutiny
Cash is an important consideration for a Business still building out capacity. OXB held £75.3m of cash at the end of June, down from £96.9m at the end of 2025, and net cash of £21.4m. Cash had fallen further to £66.8m by the end of August. Management has emphasised disciplined execution and cost control as it works towards sustained profitability.
The wider cell and gene therapy sector has endured a difficult funding environment in recent years, with many biotech developers scaling back programmes. Contract development and manufacturing organisations such as OXB depend on a healthy pipeline of client projects, so improving biotech financing conditions would be a supportive factor. Its focus on viral vectors, a critical component in many gene therapies, positions it in a specialised part of the outsourcing market where capacity and quality credentials are key differentiators.
For FTSE 250 investors, upcoming milestones include delivery against the 2026 revenue range, conversion of the expanded pipeline into contracted work and progress towards positive EBITDA. Updates on the US operations and the cost base will also be watched closely as the company works towards its 2027 targets.






Please wait processing your request...